Douglas Lane & Associates LLC Has $50.16 Million Stock Position in Elanco Animal Health Incorporated $ELAN

Key Points

• Douglas Lane & Associates LLC reduced its stake in Elanco Animal Health by 9.8%, now owning approximately 0.71% of the company, valued at $50.16 million.
• Elanco Animal Health reported $0.26 earnings per share for the last quarter, exceeding the consensus estimate of $0.20, with a year-over-year revenue growth of 4.8%.
• Analyst ratings for Elanco show a consensus of Moderate Buy, with price targets ranging from $16.00 to $18.00, reflecting positive sentiment among analysts.

Douglas Lane & Associates LLC decreased its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 9.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,512,675 shares of the company's stock after selling 382,515 shares during the period. Douglas Lane & Associates LLC owned 0.71% of Elanco Animal Health worth $50,161,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Yousif Capital Management LLC bought a new position in shares of Elanco Animal Health during the first quarter valued at approximately $119,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Elanco Animal Health in the first quarter valued at approximately $111,000. Comerica Bank boosted its position in shares of Elanco Animal Health by 46.4% during the first quarter. Comerica Bank now owns 49,680 shares of the company's stock worth $522,000 after purchasing an additional 15,754 shares in the last quarter. SG Americas Securities LLC bought a new stake in Elanco Animal Health during the 1st quarter worth about $891,000. Finally, GAMMA Investing LLC grew its stake in Elanco Animal Health by 1,743.8% in the 1st quarter. GAMMA Investing LLC now owns 12,390 shares of the company's stock valued at $130,000 after buying an additional 11,718 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Price Performance

NYSE:ELAN traded up $0.06 during trading hours on Friday, hitting $19.16. 1,243,926 shares of the stock traded hands, compared to its average volume of 5,980,896. The stock has a 50 day moving average price of $16.68 and a 200 day moving average price of $13.39. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $19.26. The company has a market cap of $9.52 billion, a price-to-earnings ratio of 22.17, a price-to-earnings-growth ratio of 3.42 and a beta of 1.62. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same period in the prior year, the firm posted $0.30 earnings per share. The company's quarterly revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Stifel Nicolaus lifted their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. UBS Group raised their target price on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Wall Street Zen upgraded Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Finally, Leerink Partnrs raised Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Elanco Animal Health currently has a consensus rating of "Moderate Buy" and an average price target of $17.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.